MCID: OBS002
MIFTS: 64

Obsessive-Compulsive Disorder

Categories: Genetic diseases, Mental diseases, Neuronal diseases

Aliases & Classifications for Obsessive-Compulsive Disorder

MalaCards integrated aliases for Obsessive-Compulsive Disorder:

Name: Obsessive-Compulsive Disorder 54 12 29 52 41 42 14 69
Obsessive-Compulsive Disorder, Protection Against 54 13
Obsessive Compulsive Disorder 12
Obsessive Compulsive Behavior 69
Anancastic Neurosis 12

Characteristics:

OMIM:

54
Inheritance:
autosomal dominant form


HPO:

32
obsessive-compulsive disorder:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 54 164230
Disease Ontology 12 DOID:10933
ICD10 33 F42
ICD9CM 35 300.3
MeSH 42 D009771
NCIt 47 C88411
UMLS 69 C0028768

Summaries for Obsessive-Compulsive Disorder

MedlinePlus : 41 obsessive-compulsive disorder (ocd) is a type of anxiety disorder. if you have ocd, you have frequent, upsetting thoughts called obsessions. to try to control the thoughts, you feel an overwhelming urge to repeat certain rituals or behaviors. these are called compulsions. examples of obsessions are a fear of germs or a fear of being hurt. compulsions include washing your hands, counting, checking on things, or cleaning. with ocd, the thoughts and rituals cause distress and get in the way of your daily life. researchers think brain circuits may not work properly in people who have ocd. it tends to run in families. the symptoms often begin in children or teens. treatments include therapy, medicines, or both. one type of therapy, cognitive behavioral therapy, is useful for treating ocd. nih: national institute of mental health

MalaCards based summary : Obsessive-Compulsive Disorder, also known as obsessive-compulsive disorder, protection against, is related to transsexualism and multiple personality disorder, and has symptoms including obsessive-compulsive behavior, fatigue and sleep disturbances. An important gene associated with Obsessive-Compulsive Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Transmission across Chemical Synapses and Circadian entrainment. The drugs Topiramate and Citalopram have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and testes, and related phenotypes are Decreased viability and behavior/neurological

Disease Ontology : 12 An anxiety disorder that involves unwanted and repeated thoughts, feelings, ideas, sensations (obsessions), or behaviors that make them feel driven to do something (compulsions).

OMIM : 54
Obsessive-compulsive disorder (OCD) is characterized by recurring obsessions and/or compulsions and has been estimated to affect nearly 5 million people in the United States (Karno et al., 1988). Evidence for a strong genetic component in OCD comes from twin studies, family genetics studies, and segregation analyses, as reviewed by Alsobrook et al. (2002). Zhang et al. (2002) suggested that hoarding is likely to be an evolutionarily conserved trait that, in times of adversity, was associated with increased survival and reproductive fitness. However, extreme forms of this trait are associated with marked disability and poor response to treatment (Black et al., 1998; Mataix-Cols et al., 1999). (164230)

Related Diseases for Obsessive-Compulsive Disorder

Diseases related to Obsessive-Compulsive Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 194)
id Related Disease Score Top Affiliating Genes
1 transsexualism 30.6 BDNF HTR1A HTR3A
2 multiple personality disorder 30.5 DRD4 MAOA
3 pervasive developmental disorder 30.2 BDNF COMT DRD4 OXT SLC6A3 SLC6A4
4 obsessive-compulsive personality disorder 29.9 BDNF COMT HTR1A HTR1B HTR2A HTR2C
5 personality disorder 29.6 BDNF COMT DRD2 DRD4 HTR1A HTR2A
6 schizophrenia 27.8 BDNF COMT DRD2 DRD4 HTR1A HTR1B
7 trichotillomania 11.6
8 anxiety disorder 11.5
9 gilles de la tourette syndrome 11.4
10 autism spectrum disorder 11.4
11 pandas 11.4
12 chromosome 15q11.2 deletion syndrome 11.0
13 mental retardation, autosomal dominant 23 11.0
14 sydenham chorea 11.0
15 succinic semialdehyde dehydrogenase deficiency 11.0
16 basal ganglia disease 11.0
17 dystonia, dopa-responsive, with or without hyperphenylalaninemia 11.0
18 neurogenic bladder 10.8 HTR2A MAOA SLC6A4
19 paranoid personality disorder 10.8 HTR1A HTR2A
20 hyperthyroxinemia 10.8 DRD2 HTR2A SLC6A4
21 polyneuropathy 10.7 HTR1A HTR2A
22 teebi kaurah syndrome 10.7 COMT DRD2 HTR2A
23 intracranial cavernous angioma 10.7 DRD2 SLC6A3 SLC6A4
24 hodgkin's granuloma 10.7 HTR1A HTR2A
25 ulcerative colitis 10.7 BDNF COMT DRD2
26 chromosome 11p13 deletion syndrome, distal 10.7 BDNF COMT HTR2A SLC6A4
27 angiokeratoma of mibelli 10.7 HTR1A MAOA SLC6A4
28 c8 deficiency, type ii 10.7 COMT DRD2 DRD4
29 brain meningioma 10.7 BDNF COMT DRD2
30 ring chromosome 14 syndrome 10.7 COMT MAOA
31 amyloidosis, finnish type 10.7 COMT MAOA SGCE
32 allergic hypersensitivity disease 10.6 DRD2 HTR1A HTR2A
33 vascular cancer 10.6 DRD2 HTR1A HTR2A
34 conjunctival pigmentation 10.6 MAOA SLC6A4
35 body dysmorphic disorder 10.6
36 hallucinogen dependence 10.6 BDNF DRD2 SLC6A4
37 hypertrophy of breast 10.6 DRD4 OXT SLC6A3
38 acute female pelvic peritonitis 10.6 DRD2 SLC6A3 SLC6A4
39 atypical autism 10.6 BDNF OXT SLC6A4
40 hepatic angiomyolipoma 10.6 BDNF HTR2A SLC6A3 SLC6A4
41 splenic abscess 10.6 DRD2 HTR2A SLC6A3 SLC6A4
42 uterus intravascular leiomyomatosis 10.6 COMT HTR1A MAOA SLC6A4
43 alcoholic liver cirrhosis 10.6 BDNF DRD2 DRD4 SLC6A4
44 abnormal pupillary function 10.6 HTR1A HTR3A
45 rhinoscleroma 10.5 COMT DRD2
46 anosognosia 10.5 COMT DRD2 HTR1A SLC6A4
47 panic disorder 10.5
48 mandibular cancer 10.5 HTR1A HTR3A SLC6A4
49 eosinophilia-myalgia syndrome 10.5 BDNF DRD2 DRD4 SLC6A3
50 pelvic inflammatory disease 10.5 DRD2 HTR2C SLC6A4

Comorbidity relations with Obsessive-Compulsive Disorder via Phenotypic Disease Network (PDN):


Anxiety Disorder Dependent Personality Disorder
Dysthymic Disorder Generalized Anxiety Disorder
Hypothyroidism Obsessive-Compulsive Personality Disorder
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Obsessive-Compulsive Disorder:



Diseases related to Obsessive-Compulsive Disorder

Symptoms & Phenotypes for Obsessive-Compulsive Disorder

Symptoms via clinical synopsis from OMIM:

54

Neuro:
obsessive-compulsive disorder


Clinical features from OMIM:

164230

Human phenotypes related to Obsessive-Compulsive Disorder:

32
id Description HPO Frequency HPO Source Accession
1 obsessive-compulsive behavior 32 HP:0000722

UMLS symptoms related to Obsessive-Compulsive Disorder:


fatigue, sleep disturbances, photophobia, psychiatric symptom, mental and behavioral signs and symptoms, personality changes, restlessness, pseudobulbar behavioral symptoms

GenomeRNAi Phenotypes related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.1 HTR1A HTR3A SLC6A4
2 Decreased viability GR00381-A-3 9.1 HTR1A HTR3A SLC6A4

MGI Mouse Phenotypes related to Obsessive-Compulsive Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.43 BDNF COMT DLGAP3 DRD2 DRD4 HTR1A
2 homeostasis/metabolism MP:0005376 10.2 BDNF COMT DRD2 DRD4 HTR1A HTR2C
3 cardiovascular system MP:0005385 10.13 COMT DRD2 HTR1A HTR1B MAOA OXT
4 growth/size/body region MP:0005378 10.11 BDNF DRD2 HTR1B HTR2C HTR3A OXT
5 endocrine/exocrine gland MP:0005379 10.06 BDNF COMT DRD2 HTR1B HTR2A HTR3A
6 integument MP:0010771 9.96 BDNF DLGAP3 SLC6A3 DRD2 SLC6A4 HTR2C
7 adipose tissue MP:0005375 9.88 DRD2 HTR2C OXT TPH1 TPH2
8 nervous system MP:0003631 9.86 DRD2 DRD4 HTR1A HTR2C HTR3A MAOA
9 muscle MP:0005369 9.81 DRD2 HTR1B HTR2A HTR2C HTR3A SGCE
10 taste/olfaction MP:0005394 8.92 BDNF DRD2 SLC6A3 TPH2

Drugs & Therapeutics for Obsessive-Compulsive Disorder

Drugs for Obsessive-Compulsive Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 212)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Topiramate Approved Phase 4,Phase 3 97240-79-4 5284627
2
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1 59729-33-8 2771
3
Fluvoxamine Approved, Investigational Phase 4,Phase 3 54739-18-3 3404 5324346
4
Clomipramine Approved, Vet_approved Phase 4,Phase 3,Phase 2 303-49-1 2801
5
Cycloserine Approved Phase 4,Phase 3,Phase 2,Early Phase 1 68-41-7 401 6234
6
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
7
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2 54910-89-3 3386
8
Haloperidol Approved Phase 4 52-86-8 3559
9
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
10
Norepinephrine Approved Phase 4,Phase 3 51-41-2 439260
11
Paroxetine Approved, Investigational Phase 4,Phase 3 61869-08-7 43815
12
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
13
Sertraline Approved Phase 4,Phase 3,Phase 2,Phase 1 79617-96-2 68617
14
Ondansetron Approved Phase 4,Phase 2 99614-02-5 4595
15
Methylphenidate Approved, Investigational Phase 4,Phase 2 113-45-1 4158
16
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
17
Ethanol Approved Phase 4,Phase 2,Phase 3 64-17-5 702
18 Piracetam Approved Phase 4,Phase 2,Phase 3 7491-74-9
19
Aripiprazole Approved, Investigational Phase 4,Phase 2 129722-12-9 60795
20
Acetylcysteine Approved, Investigational Phase 4,Phase 2 616-91-1 12035
21
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
22
Propranolol Approved, Investigational Phase 4 525-66-6 4946
23 Etiracetam Investigational Phase 4,Phase 2,Phase 3 33996-58-6
24
Maleic acid Experimental Phase 4,Phase 3 110-16-7 444266
25 Anticonvulsants Phase 4,Phase 3,Phase 2
26 Anti-Obesity Agents Phase 4,Phase 3
27 Neuroprotective Agents Phase 4,Phase 3,Phase 2
28 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
29 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Antidepressive Agents, Second-Generation Phase 4,Phase 3,Phase 2,Phase 1
31 Antiparkinson Agents Phase 4,Phase 3,Phase 1,Phase 2
32 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Cholinergic Antagonists Phase 4,Phase 3,Phase 2,Phase 1
35 Muscarinic Antagonists Phase 4,Phase 3,Phase 2,Phase 1
36 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
38 Parasympatholytics Phase 4,Phase 3,Phase 2,Phase 1
39 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
41
Serotonin Phase 4,Phase 3,Phase 2,Phase 1 50-67-9 5202
42 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
44 Anti-Anxiety Agents Phase 4,Phase 3,Phase 1,Phase 2
45 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Cytochrome P-450 CYP1A2 Inhibitors Phase 4,Phase 3
47 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2
48 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Antidepressive Agents, Tricyclic Phase 4,Phase 3,Phase 2
50 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 384)

id Name Status NCT ID Phase Drugs
1 Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder Unknown status NCT00211744 Phase 4 topiramate
2 Treatment Youth With Obsessive-Compulsive Disorder Unknown status NCT00708240 Phase 4 Escitalopram
3 Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD) Unknown status NCT00743834 Phase 4 Luvox CR
4 Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study Unknown status NCT00708396 Phase 4 Escitalopram
5 Escitalopram for the Treatment of Obsessive Compulsive Disorder (OCD) Completed NCT00116532 Phase 4 Escitalopram
6 Treatment of Obsessive-Compulsive Disorder Completed NCT00000373 Phase 4 olanzapine + fluoxetine;placebo + fluoxetine
7 Duloxetine for the Treatment of Obsessive Compulsive Disorder (OCD) Completed NCT00464698 Phase 4 Duloxetine
8 Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder Completed NCT00854919 Phase 4 atypical antipsychotic drug
9 Quetiapine Augmentation Versus Clomipramine Augmentation of SSRI for Obsessive-Compulsive Disorder Patients Completed NCT00564564 Phase 4 Quetiapine;Clomipramine
10 Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment Completed NCT00466609 Phase 4 clomipramine and fluoxetine;quetiapine and fluoxetine;placebo and fluoxetine
11 Deep Brain Stimulation for Obsessive Compulsive Disorder (OCD PMCF) Completed NCT01135745 Phase 4
12 Effectiveness of Sertraline and Cognitive Behavioral Therapy in Treating Pediatric Obsessive-Compulsive Disorder Completed NCT00382291 Phase 4 Regular Titration;Placebo;Slow Titration
13 Group Cognitive Behavioral Therapy Versus Fluoxetine for Obsessive-Compulsive Disorder: a Practical Trial Completed NCT00680602 Phase 4 SSRI (fluoxetine, sertraline, paroxetine, citalopram)
14 Ondansetron in Treatment Resistant Obsessive Compulsive Disorder (OCD) Completed NCT00796497 Phase 4 ondansetron
15 Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder Completed NCT00723060 Phase 4 escitalopram
16 D-Cycloserine as an Adjunct to Internet-CBT for OCD Completed NCT01649895 Phase 4 D-Cycloserine;Placebo
17 Augmentation in Tx-resistant OCD: an Open Label Trial Completed NCT00590642 Phase 4
18 Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder Completed NCT02194075 Phase 4 Fluvoxamine+Methylphenidate hydrochloride;Fluvoxamine+sugar pill
19 Ondansetron Augmentation in Treatment-resistant OCD Completed NCT01303536 Phase 4 Ondansetron
20 Antidepressant Safety in Kids Study Completed NCT00395213 Phase 4 Selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) medications
21 Escitalopram in Schizophrenia in OCD- Open Label Study Completed NCT00456937 Phase 4 Escitalopram
22 Amoxicillin for the Treatment of Pediatric Autoimmune Disorders Associated With Streptococcal Infections Completed NCT00001658 Phase 4 Amoxicillin
23 Olanzapine in the Treatment of Hair Pulling (Trichotillomania) Completed NCT00182507 Phase 4 Olanzapine
24 Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety Completed NCT00352469 Phase 4 Seroquel XR
25 Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder Completed NCT00265109 Phase 4 Levetiracetam
26 FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders Completed NCT01028820 Phase 4 Aripiprazole
27 Efficacy of Adding Topiramate to Current Treatment in Refractory Obsessive Compulsive Disorder (OCD) Recruiting NCT00182520 Phase 4 Topiramate;placebo
28 Probiotic Treatment in Adult Obsessive-Compulsive Disorder Recruiting NCT02334644 Phase 4
29 A Study of Pregabalin (Lyrica) Augmentation in Serotonin Reuptake Inhibitor-Refractory Obsessive Compulsive Disorder Recruiting NCT00994786 Phase 4 pregabalin;Placebo
30 Fear Conditioned Response in Healthy Subjects and in OCD Patients Pre and Post Treatment With Sertraline. Recruiting NCT03068429 Phase 4 Sertraline Hydrochloride
31 Brief Intervention for OCD Fears Recruiting NCT02790710 Phase 4 Propanolol;Placebo
32 Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients Recruiting NCT02022709 Phase 4 Fluoxetine;Sertraline;Paroxetine;Citalopram;Fluvoxamine
33 Effects of Ondansetron in Obsessive-compulsive and Tic Disorders Recruiting NCT03239210 Phase 4 Ondansetron;Placebo
34 Translational Approach to the Understanding and Treatment of Obsessive-Compulsive Disorder (OCD). Can D-Cycloserine Enhance and Stabilize the Treatment-response in Relapsed and Non-responding OCD-patients? Active, not recruiting NCT02656342 Phase 4 D-Cycloserine;Placebo
35 Attaining and Maintaining Wellness in Obsessive-compulsive Disorder Active, not recruiting NCT01686087 Phase 4
36 The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia Active, not recruiting NCT01339858 Phase 4 N-Acetyl Cysteine
37 Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders Active, not recruiting NCT00182533 Phase 4 Sertraline;Placebo
38 Fluvoxamine Maleate in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents Terminated NCT00352768 Phase 4 Fluvoxamine maleate;Placebo
39 Fluoxetine for Obsessive-Compulsive Disorder in Children and Adolescents With Bipolar Disorder Terminated NCT00592852 Phase 4 fluoxetine
40 A Phase 3 Study of SME3110 in Pediatric/Adolescent Subjects With Obsessive Compulsive Disorder Completed NCT01933919 Phase 3 fluvoxamine maleate;placebo
41 Study of Sequentially Applied Repetitive Transcranial Magnetic Stimulation in Obsessive- Compulsive Disorders Completed NCT00932204 Phase 3
42 Quetiapine Augmentation in Severe Obsessive Compulsive Disorder Completed NCT00254735 Phase 3 quetiapine fumarate;SSRI/Clomipramine
43 Study to Determine the Efficacy and Safety of Adjunctive Topiramate in the Treatment of Obsessive-Compulsive Disorder Completed NCT00187928 Phase 3 Topiramate
44 Comparison of DBS Targets in Obsessive-compulsive Disorder Completed NCT01807403 Phase 3
45 Treatment of Obsessive-Compulsive Disorder (OCD) in Children Completed NCT00000384 Phase 3 Sertraline
46 A Controlled Trial of Daily Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder Completed NCT00369642 Phase 3
47 Tolerability and Efficacy of High Dose Escitalopram for the Treatment of Obsessive-Compulsive Disorder (OCD) Completed NCT00305500 Phase 3 escitalopram
48 Treatment of Obsessive Compulsive Disorder in Children Completed NCT00074815 Phase 3 Serotonin reuptake inhibitors management
49 Family Based Treatment of Early Childhood Obsessive Compulsive Disorder Completed NCT00055068 Phase 3
50 Comparing the Effectiveness of Two Family-based Therapies in Treating Young Children With Obsessive-Compulsive Disorder Completed NCT00533806 Phase 3

Search NIH Clinical Center for Obsessive-Compulsive Disorder

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: obsessive-compulsive disorder

Genetic Tests for Obsessive-Compulsive Disorder

Genetic tests related to Obsessive-Compulsive Disorder:

id Genetic test Affiliating Genes
1 Obsessive-Compulsive Disorder 29

Anatomical Context for Obsessive-Compulsive Disorder

MalaCards organs/tissues related to Obsessive-Compulsive Disorder:

39
Brain, Cortex, Testes, Subthalamic Nucleus, Skin, Prefrontal Cortex, Cingulate Cortex

Publications for Obsessive-Compulsive Disorder

Articles related to Obsessive-Compulsive Disorder:

(show top 50) (show all 1105)
id Title Authors Year
1
Cognitive control networks in OCD: A resting-state connectivity study in unmedicated patients with obsessive-compulsive disorder and their unaffected relatives. ( 28918693 )
2017
2
Pathophysiology of refractory obsessive-compulsive disorder: A study of visual search combined with overactive performance monitoring. ( 28072701 )
2017
3
Face and Object Perception in Body Dysmorphic Disorder versus Obsessive-Compulsive Disorder: The Mooney Faces Task. ( 28528596 )
2017
4
Compulsive skin-picking behavior after deep brain stimulation in a patient with refractory obsessive-compulsive disorder: A case report. ( 28885367 )
2017
5
Correction to: Motivala etA al., Relationships between obsessive-compulsive disorder, depression and functioning before and after exposure and response prevention therapy. ( 28949272 )
2017
6
Altered serotonergic and GABAergic neurotransmission in a mice model of obsessive-compulsive disorder. ( 28916503 )
2017
7
Anxiety sensitivity as a predictor of outcome in the treatment of obsessive-compulsive disorder. ( 28505489 )
2017
8
Pedophilia-Themed Obsessive-Compulsive Disorder: Assessment, Differential Diagnosis, and Treatment with Exposure and Response Prevention. ( 28822003 )
2017
9
Investigating the role of anticipatory reward and habit strength in obsessive-compulsive disorder. ( 28065178 )
2017
10
Prevalence and correlates of obsessive-compulsive disorder and subthreshold obsessive-compulsive disorder among college students in Kerala, India. ( 28529361 )
2017
11
Embracing Uncertainty as a First-Year Therapist Treating a Patient Who Has Obsessive-Compulsive Disorder. ( 28457206 )
2017
12
Co-morbid obsessive-compulsive disorder and depression: a Bayesian network approach. ( 28052778 )
2017
13
Tics and obsessive-compulsive disorder in relation to diet: Two case reports. ( 28870689 )
2017
14
Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials. ( 28947609 )
2017
15
Oxytocin receptor gene polymorphisms exert a modulating effect on the onset age in patients with obsessive-compulsive disorder. ( 28915380 )
2017
16
Cost-effectiveness of deep brain stimulation versus treatment as usual for obsessive-compulsive disorder. ( 28457837 )
2017
17
Volitional saccade performance in a large sample of patients with obsessive-compulsive disorder and unaffected first-degree relatives. ( 28481032 )
2017
18
Diagnostic validity of early-onset obsessive-compulsive disorder in the Danish Psychiatric Central Register: findings from a cohort sample. ( 28928194 )
2017
19
New Directions in the Use of Brain Stimulation Interventions in Patients with Obsessive-Compulsive Disorder. ( 28474552 )
2017
20
Cost-effectiveness of therapist-guided internet-delivered cognitive behaviour therapy for paediatric obsessive-compulsive disorder: results from a randomised controlled trial. ( 28515196 )
2017
21
Vitamin B12, folic acid, homocysteine and vitamin D levels in children and adolescents with obsessive compulsive disorder. ( 28477545 )
2017
22
Parental age and the risk of obsessive compulsive disorder and Tourette syndrome / chronic tic disorder in a nationwide population-based sample. ( 28738196 )
2017
23
Quality of Life in Children and Youth with Obsessive-Compulsive Disorder. ( 28910139 )
2017
24
Separating obsessive-compulsive disorder from the self. A qualitative study of family member perceptions. ( 28882118 )
2017
25
Functional and structural connectivity of the amygdala in obsessive-compulsive disorder. ( 28018851 )
2017
26
Mechanisms of cognitive-behavioral therapy for obsessive-compulsive disorder involve robust and extensive increases in brain network connectivity. ( 28872637 )
2017
27
Choreatic side-effects of deep brain stimulation of the anteromedial subthalamic nucleus for treatment-resistant obsessive-compulsive disorder: a case report. ( 28532905 )
2017
28
Unpacking the role of self-reported compulsivity and impulsivity in obsessive-compulsive disorder. ( 28487007 )
2017
29
Resting-state functional connectivity between right anterior insula and right orbital frontal cortex correlate with insight level in obsessive-compulsive disorder. ( 28458998 )
2017
30
Planning functioning and impulsiveness in obsessive-compulsive disorder. ( 28466133 )
2017
31
Enhanced error related negativity amplitude in medication-naA^ve, comorbidity-free obsessive compulsive disorder. ( 28941812 )
2017
32
Overvalued ideation in adolescents with obsessive-compulsive disorder. ( 28528243 )
2017
33
C9orf72 hexanucleotide repeat expansions are not a common cause of obsessive-compulsive disorder. ( 28320191 )
2017
34
Association of the functional serotonin transporter haplotype with familial form of obsessive compulsive disorder in Iranian patients. ( 28691545 )
2017
35
Neurocognitive Function in Pediatric Obsessive-Compulsive Disorder. ( 28090807 )
2017
36
Family accommodation of anxiety symptoms in youth undergoing intensive multimodal treatment for anxiety disorders and obsessive-compulsive disorder: Nature, clinical correlates, and treatment response. ( 28892781 )
2017
37
Shared and disorder-specific task-positive and default mode network dysfunctions during sustained attention in paediatric Attention-Deficit/Hyperactivity Disorder and obsessive/compulsive disorder. ( 28529874 )
2017
38
Executive function predicts cognitive-behavioral therapy response in childhood obsessive-compulsive disorder. ( 28881220 )
2017
39
The Nepean Belief Scale: preliminary reliability and validity in obsessive-compulsive disorder. ( 28885070 )
2017
40
A review of the role of serotonin system genes in obsessive-compulsive disorder. ( 28576508 )
2017
41
Role of Glutamatergic System in Obsessive-Compulsive Disorder with Possible Therapeutic Implications. ( 28950396 )
2017
42
Obsessive-compulsive disorder has a reduced placebo (and antidepressant) response compared to other anxiety disorders: A meta-analysis. ( 28477500 )
2017
43
Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials. ( 28903922 )
2017
44
Deep brain stimulation of the anterior limb of the internal capsule for treatment of therapy-refractory obsessive compulsive disorder (OCD): a case study highlighting neurocognitive and psychiatric changes. ( 28457185 )
2017
45
Effectiveness of Low-Dose Aripiprazole Monotherapy in the Treatment for an Adolescent With Obsessive-Compulsive Disorder. ( 28922290 )
2017
46
A cross-cultural clinical comparison between subjects with obsessive-compulsive disorder from the United States and Brazil. ( 28457988 )
2017
47
The development and validation of static and adaptive screeners to measure the severity of panic disorder, social anxiety disorder, and obsessive compulsive disorder. ( 28370638 )
2017
48
Peripheral SLC6A4 Gene Expression in Obsessive-Compulsive Disorder in the Han Chinese Population. ( 28904509 )
2017
49
L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study. ( 28485008 )
2017
50
Neuronal nitric oxide synthase polymorphisms in obsessive-compulsive disorder. ( 27739347 )
2017

Variations for Obsessive-Compulsive Disorder

Copy number variations for Obsessive-Compulsive Disorder from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 77765 13 47471310 47471410 Deletion Obsessive-compulsive disorder
2 160222 22 11800000 24300000 Deletion Obsessive-compulsive disorder

Expression for Obsessive-Compulsive Disorder

Search GEO for disease gene expression data for Obsessive-Compulsive Disorder.

Pathways for Obsessive-Compulsive Disorder

Pathways related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

(show all 16)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.84 COMT DLGAP3 MAOA SLC1A1 SLC6A3 SLC6A4
2
Show member pathways
12.6 COMT DRD2 DRD4 MAOA SLC1A1 SLC6A3
3 12.4 COMT HTR1A SLC1A1 TPH1 TPH2
4
Show member pathways
12.13 BDNF DRD2 HTR1A HTR1B
6 11.97 BDNF HTR1A HTR2A HTR3A MAOA SLC6A4
7
Show member pathways
11.85 BDNF DRD2 MAOA SLC6A3
8
Show member pathways
11.79 DRD2 DRD4 HTR1A HTR1B HTR2A HTR2C
9 11.66 HTR1A HTR1B HTR2A HTR2C HTR3A MAOA
10
Show member pathways
11.3 MAOA SLC6A3 SLC6A4 TPH2
11
Show member pathways
11.05 COMT MAOA SLC6A3 SLC6A4
12
Show member pathways
10.95 COMT MAOA TPH1
13 10.86 HTR2A HTR2C
14 10.72 HTR1A HTR1B HTR2A HTR2C HTR3A MAOA
15 10.69 COMT MAOA
16
Show member pathways
10.68 COMT MAOA

GO Terms for Obsessive-Compulsive Disorder

Cellular components related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.8 COMT DLGAP3 DRD2 DRD4 HTR1A HTR1B
2 axon GO:0030424 9.55 COMT DRD2 HTR2A HTR3A SLC6A3
3 integral component of plasma membrane GO:0005887 9.32 DRD2 DRD4 HTR1A HTR1B HTR2A HTR2C
4 integral component of membrane GO:0016021 10.1 COMT DRD2 DRD4 HTR1A HTR1B HTR2A

Biological processes related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
id Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.98 HTR1B HTR2A HTR2C SLC1A1
2 cellular calcium ion homeostasis GO:0006874 9.89 DRD4 HTR2A HTR2C
3 locomotory behavior GO:0007626 9.87 DRD2 HTR2C SLC6A3
4 circadian rhythm GO:0007623 9.87 SLC6A4 TPH1 TPH2
5 response to ethanol GO:0045471 9.86 DRD2 HTR1B HTR3A SLC6A3
6 memory GO:0007613 9.84 HTR2A OXT SLC6A4
7 positive regulation of synapse assembly GO:0051965 9.83 BDNF OXT SLITRK1
8 synapse assembly GO:0007416 9.83 BDNF DRD2 SLITRK1
9 positive regulation of fat cell differentiation GO:0045600 9.8 HTR2A HTR2C TPH1
10 social behavior GO:0035176 9.8 DRD4 OXT SLC6A4
11 response to drug GO:0042493 9.8 COMT DRD2 HTR1B HTR2A HTR2C SLC6A3
12 feeding behavior GO:0007631 9.79 DRD2 HTR1B HTR2C
13 release of sequestered calcium ion into cytosol GO:0051209 9.77 DRD2 HTR2A HTR2C
14 response to iron ion GO:0010039 9.72 DRD2 SLC6A3
15 negative regulation of protein secretion GO:0050709 9.72 DRD2 DRD4
16 negative regulation of cAMP biosynthetic process GO:0030818 9.72 DRD4 HTR1B
17 behavioral response to ethanol GO:0048149 9.72 DRD2 DRD4
18 behavioral fear response GO:0001662 9.72 DRD4 HTR1A HTR2C
19 positive regulation of kinase activity GO:0033674 9.71 DRD4 HTR2A
20 bone remodeling GO:0046849 9.71 HTR1B TPH1
21 neurotransmitter biosynthetic process GO:0042136 9.71 SLC6A3 SLC6A4
22 negative regulation of voltage-gated calcium channel activity GO:1901386 9.71 DRD2 DRD4
23 response to amphetamine GO:0001975 9.71 DRD2 DRD4 OXT
24 grooming behavior GO:0007625 9.7 DRD2 OXT
25 ammonium transmembrane transport GO:0072488 9.7 SLC6A3 SLC6A4
26 prepulse inhibition GO:0060134 9.7 DRD2 SLC6A3
27 positive regulation of renal sodium excretion GO:0035815 9.69 DRD2 OXT
28 G-protein coupled receptor internalization GO:0002031 9.69 DRD2 HTR1B
29 regulation of dopamine secretion GO:0014059 9.69 DRD2 HTR1B HTR2A
30 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.68 DRD2 DRD4
31 sleep GO:0030431 9.68 HTR2A OXT
32 neurotransmitter catabolic process GO:0042135 9.68 COMT MAOA
33 catecholamine metabolic process GO:0006584 9.67 COMT MAOA
34 adenohypophysis development GO:0021984 9.67 DRD2 SLC6A3
35 monoamine transport GO:0015844 9.67 SLC6A3 SLC6A4
36 behavioral response to cocaine GO:0048148 9.67 DRD2 DRD4 HTR2A
37 aromatic amino acid family metabolic process GO:0009072 9.65 TPH1 TPH2
38 drinking behavior GO:0042756 9.65 HTR1B OXT
39 vasoconstriction GO:0042310 9.65 HTR1A HTR1B SLC6A4
40 dopamine uptake involved in synaptic transmission GO:0051583 9.64 SLC6A3 SLC6A4
41 sperm ejaculation GO:0042713 9.64 OXT SLC6A4
42 regulation of hormone secretion GO:0046883 9.63 HTR1A HTR2A
43 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.63 DRD2 HTR1B HTR2A
44 indolalkylamine biosynthetic process GO:0046219 9.62 TPH1 TPH2
45 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.61 HTR1A HTR1B
46 dopamine metabolic process GO:0042417 9.61 COMT DRD2 DRD4
47 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.6 HTR2A HTR2C
48 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.58 DRD2 DRD4
49 serotonin biosynthetic process GO:0042427 9.58 TPH1 TPH2
50 regulation of dopamine metabolic process GO:0042053 9.58 DRD4 HTR1A SLC6A3

Molecular functions related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

(show all 16)
id Name GO ID Score Top Affiliating Genes
1 signal transducer activity GO:0004871 9.85 DRD2 DRD4 HTR1A HTR1B HTR2A HTR2C
2 symporter activity GO:0015293 9.73 SLC1A1 SLC6A3 SLC6A4
3 neurotransmitter receptor activity GO:0030594 9.56 HTR1A HTR1B HTR2A HTR2C
4 neurotransmitter:sodium symporter activity GO:0005328 9.55 SLC6A3 SLC6A4
5 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.52 DRD2 DRD4
6 monoamine transmembrane transporter activity GO:0008504 9.51 SLC6A3 SLC6A4
7 dopamine binding GO:0035240 9.5 DRD2 DRD4 SLC6A3
8 dopamine neurotransmitter receptor activity GO:0004952 9.49 DRD2 DRD4
9 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.48 TPH1 TPH2
10 dopamine:sodium symporter activity GO:0005330 9.46 SLC6A3 SLC6A4
11 G-protein coupled serotonin receptor activity GO:0004993 9.46 HTR1A HTR1B HTR2A HTR2C
12 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.43 HTR2A HTR2C
13 drug binding GO:0008144 9.43 DRD2 DRD4 HTR1B HTR2A HTR2C SLC6A3
14 tryptophan 5-monooxygenase activity GO:0004510 9.4 TPH1 TPH2
15 serotonin binding GO:0051378 9.02 HTR1A HTR1B HTR2A HTR2C HTR3A
16 G-protein coupled receptor activity GO:0004930 10.01 DRD2 DRD4 HTR1A HTR1B HTR2A HTR2C

Sources for Obsessive-Compulsive Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....